English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 8 October 2021, 15:13 HKT/SGT
Share:
    

Source: Legend Capital
Legend Capital leads ForQaly Medical's Series B financing

HONG KONG, Oct 8, 2021 - (ACN Newswire) - ForQaly Medical (hereinafter referred to as "ForQaly"), located in Shanghai Zhangjiang International Medical Zone, is a leading high-tech company focused on developing micro-traumatic circulatory assistant devices. Recently, it completed its Series B fundraising led by Legend Capital, followed by CD Capital, SAIF Partners, Chengwei Chuangban and Co-win Ventures. Existing investors Lilly Asia Ventures and Kaitai Capital also participated in the funding round.

This round of financing will be applied to promote the clinical research of ForQaly's existing products, so that the transvalvular ventricular assist devices (VAD) could be affordable for patients with urgent needs as early as possible. On the other hand, the capital will go for the expansion of ForQaly's research team to accelerate the parallel development of products, so that potential comprehensive solutions could be provided for high-risk PCI intraoperative protection and cardiogenic shock treatment.

Mr. Tang Zhirong, the founder of ForQaly, said: "For the past years, the clinical applications of the transvalvular VAD was uncommon in China. ForQaly, as a domestic pioneer in the field, will make full use of its resources to support pre-clinical training and ensure the quality of product clinical research, so as to collect reliable and evidence-based medicine data."

Joe Zhou, the Managing Director of Legend Capital, said: "VAD, especially the interventional one, has a huge market prospect in China. ForQaly's senior management team represented by Mr. Tang has dedicated and hardly-worked in this field for nearly 6 years with leading products launched both at home and abroad. We are glad to partner with ForQaly Medical and will establish a long-term cooperation with the company.

Legend Capital has long focused on its investment in medical devices and diagnostics, among which many portfolio companies have successfully went public at home and abroad, such as KingMed Diagnostics (603882.SH), Berry Genomics (000710.SZ), EasyDiagnosis (002932.SZ), Axonics (AXNX), CareRay Digital Medical (688607.SH), New Horizon Health (06606.HK), Singular Genomics (NASDAQ: OMIC), etc. In addition, Legend Capital has invested in a lot of leading companies in subdivisions of this field, such as Puyi Biotechnology, Reliable Med, StarSportMed, Genext, ET Healthcare, GKHT Medical Technology, GensKey, Best Brain Health, Bioheart, HeMo, Shanghai Aohua and Berry Oncology.



Topic: Press release summary
Source: Legend Capital

Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm, PE, VC & Alternatives
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Legend Capital Related News
Nov 13, 2022 10:12 HKT/SGT
Legend Capital Portfolio Company Atour Successfully Lists on Nasdaq
Nov 10, 2022 14:26 HKT/SGT
Led by Legend Capital, PureFDA Secures Over CNY100 million in the Series B Round
Nov 9, 2022 08:46 HKT/SGT
君联资本所投企业巨子生物在港交所成功上市
Nov 9, 2022 08:45 HKT/SGT
君聯資本所投企業巨子生物在港交所成功上市
Nov 7, 2022 15:49 HKT/SGT
Legend Capital Portfolio Company Giant Biogene Successfully Lists on the HKEX
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575